Journal of AdvancedMedical and Dental Sciences Research

Aim: To evaluate the impact of various topical therapies on persistent plaque psoriasis. Methods: A total of 300 individuals were recruited and split into three groups of 100 patients each. Patients in Group A were instructed to apply ammonium lactate twice daily, while patients in Group B were instructed to apply ammonium lactate in the morning and clobetasol propionate in the evening, and patients in Group C were instructed to apply topical ammonium lactate in the morning and calcipotriol in the evening. Each patient was invited to return at four and eight week’s intervals to assess therapy response both subjectively and objectively. Results: According to the physician global evaluation scale, 38 percent of patients in Group A had great responses, 16 percent had good responses, 20 percent had acceptable responses, and 26 percent had poor responses. In group B, 34 percent of patients had an exceptional reaction, 30 percent had a good response, 16 percent had a medium response, and 20 percent had a poor response. In group C, 30 percent of patients had an exceptional reaction, 29 percent had a good response, 21 percent had a medium response, and 20 percent had a bad response. Conclusion: Novel understandings of the aetiology of psoriasis have allowed for the discovery of new treatment targets. Topical treatments with specific targets are being developed and evaluated. The introduction of novel compounds and drug delivery methods will greatly broaden the therapeutic arsenal for the treatment of psoriasis. Topical treatments are the foundation of psoriasis care.